RIGL - Rigel Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
RIGL price evolution
RIGL
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $36.05 | $25.57 | $32.79 | |
| Short term investments | $13.05 | $23.98 | $24.15 | |
| Net receivables | $30.57 | $28.9 | $27.51 | $30.55 |
| Inventory | $4.78 | $8.06 | $6.58 | $5.52 |
| Total current assets | $106.47 | $94.72 | $92.49 | $99.27 |
| Long term investments | ||||
| Property, plant & equipment | $0.5 | $0.68 | $0.85 | $1.03 |
| Goodwill & intangible assets | $28.27 | $28.86 | $13.88 | |
| Total noncurrent assets | $33.69 | $34.03 | $17.96 | |
| Total investments | $13.05 | $23.98 | $24.15 | |
| Total assets | $139.42 | $128.41 | $126.52 | $117.22 |
| Current liabilities | ||||
| Accounts payable | $3.81 | $6.13 | $9.28 | $7.14 |
| Deferred revenue | $19.9 | $17.4 | $17.04 | |
| Short long term debt | $0.64 | $15.49 | $7.92 | |
| Total current liabilities | $54.31 | $58.65 | $73.2 | $53.27 |
| Long term debt | $59.76 | $59.69 | $45.01 | $52.66 |
| Total noncurrent liabilities | $99.67 | $84.99 | $92.6 | |
| Total debt | $60.33 | $60.5 | $60.58 | |
| Total liabilities | $154.06 | $158.32 | $158.19 | $145.87 |
| Shareholders' equity | ||||
| Retained earnings | -$1404.41 | -$1416.83 | -$1415.8 | -$1407.55 |
| Other shareholder equity | $0.01 | -$0.01 | -$0.01 | $0.01 |
| Total shareholder equity | -$29.91 | -$31.67 | -$28.64 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $32.79 | $24.46 | $18.89 | $30.37 |
| Short term investments | $24.15 | $33.75 | $106.08 | $26.95 |
| Net receivables | $30.55 | $40.32 | $15.47 | $15.97 |
| Inventory | $5.52 | $9.12 | $6.62 | $1.64 |
| Total current assets | $99.27 | $115.9 | $154.47 | $88.98 |
| Long term investments | ||||
| Property, plant & equipment | $1.03 | $2.79 | $11.89 | $20.57 |
| Goodwill & intangible assets | $13.88 | $14.95 | ||
| Total noncurrent assets | $17.96 | $18.38 | $12.86 | $21.39 |
| Total investments | $24.15 | $33.75 | $106.08 | $26.95 |
| Total assets | $117.22 | $134.28 | $167.33 | $110.38 |
| Current liabilities | ||||
| Accounts payable | $7.14 | $22.51 | $3.79 | $3.71 |
| Deferred revenue | $17.04 | $13.51 | $2.6 | $3.02 |
| Short long term debt | $7.92 | $1.13 | $9.89 | $8.62 |
| Total current liabilities | $53.27 | $65.21 | $63.55 | $40.84 |
| Long term debt | $52.66 | $39.45 | $20.67 | $30.47 |
| Total noncurrent liabilities | $92.6 | $82.68 | $73.4 | $35.51 |
| Total debt | $60.58 | $41.55 | $30.57 | $39.09 |
| Total liabilities | $145.87 | $147.9 | $136.95 | $76.35 |
| Shareholders' equity | ||||
| Retained earnings | -$1407.55 | -$1382.46 | -$1323.89 | -$1305.97 |
| Other shareholder equity | $0.01 | -$0.15 | -$0.1 | -$0 |
| Total shareholder equity | -$28.64 | -$13.62 | $30.37 | $34.03 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.84 | $29.53 | $35.79 | |
| Cost of revenue | $2.81 | $2.02 | $3.79 | |
| Gross Profit | $34.03 | $27.51 | $32 | |
| Operating activities | ||||
| Research & development | $5.54 | $6.03 | $3.19 | |
| Selling, general & administrative | $28.05 | $28.45 | $26.85 | |
| Total operating expenses | $33.59 | $34.48 | $30.04 | |
| Operating income | $0.45 | -$6.97 | $1.97 | |
| Income from continuing operations | ||||
| EBIT | $1 | -$6.37 | $2.64 | |
| Income tax expense | ||||
| Interest expense | $2.03 | $1.87 | $1.91 | |
| Net income | ||||
| Net income | -$1.03 | -$8.25 | $0.74 | |
| Income (for common shares) | -$1.03 | -$8.25 | $0.74 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $116.88 | $120.24 | $149.24 | $108.62 |
| Cost of revenue | $7.11 | $1.75 | $1.08 | $0.9 |
| Gross Profit | $109.77 | $118.49 | $148.15 | $107.73 |
| Operating activities | ||||
| Research & development | $24.52 | $60.27 | $65.24 | $60.1 |
| Selling, general & administrative | $105.74 | $112.45 | $91.89 | $76.6 |
| Total operating expenses | $130.26 | $174.04 | $160.65 | $136.7 |
| Operating income | -$20.49 | -$55.55 | -$12.5 | -$28.97 |
| Income from continuing operations | ||||
| EBIT | -$18.22 | -$54.87 | -$12.45 | -$28.39 |
| Income tax expense | $0.6 | |||
| Interest expense | $6.87 | $3.71 | $4.86 | $1.35 |
| Net income | ||||
| Net income | -$25.09 | -$58.57 | -$17.91 | -$29.74 |
| Income (for common shares) | -$25.09 | -$58.57 | -$17.91 | -$29.74 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1.03 | -$8.25 | $0.74 | |
| Operating activities | ||||
| Depreciation | $0.61 | $0.4 | $0.29 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.53 | $5.13 | $1.93 | |
| Total cash flows from operations | $0.3 | -$5.01 | -$6.24 | |
| Investing activities | ||||
| Capital expenditures | -$0.22 | -$0.14 | $0.11 | |
| Investments | $11.15 | $0.45 | -$6.98 | |
| Total cash flows from investing | $15.04 | $10.93 | $0.31 | -$6.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.25 | $0.09 | $0.49 | |
| Net borrowings | ||||
| Total cash flows from financing | -$13.11 | -$0.75 | -$2.51 | $0.49 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $18.91 | $10.48 | -$7.21 | -$12.63 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$25.09 | -$58.57 | -$17.91 | -$29.74 |
| Operating activities | ||||
| Depreciation | $1.24 | $1 | $1.16 | $0.71 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.81 | $12.38 | $9.49 | $7.3 |
| Total cash flows from operations | -$5.74 | -$73.76 | $5.88 | -$52.19 |
| Investing activities | ||||
| Capital expenditures | $0.26 | $0.44 | -$0.63 | -$1.26 |
| Investments | $10.44 | $72.33 | -$79.41 | $48.73 |
| Total cash flows from investing | -$4.3 | $72.78 | -$80.04 | $47.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.05 | $2.12 | $4.78 | $2.6 |
| Net borrowings | $19.95 | $19.54 | $9.97 | |
| Total cash flows from financing | $18.37 | $6.55 | $62.67 | $12.57 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $8.33 | $5.57 | -$11.48 | $7.85 |
News
Fundamentals
| Market cap | $379.91M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 17.61M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -5.09 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.96 |
| Quick ratio | 1.87 |